Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00049608 · ClinicalTrials.gov registry record · Phase 1
Gemcitabine Combined With Mistletoe in Treating Patients With Advanced Solid Tumors
A Phase 1 study, sponsored by National Center for Complementary and Integrative Health (NCCIH).
- Terminated
- Registry status
- Phase 1
- Development phase
- 51
- Enrollment target
NCT00049608: Clinical Trial Phase 1 study, sponsored by National Center for Complementary and Integrative Health (NCCIH).
NCT00049608 is a Phase 1 study that was terminated before completion, run by National Center for Complementary and Integrative Health (NCCIH). The registered enrollment target is 51 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (15% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00049608, a Phase 1 study, was terminated before completion, sponsored by National Center for Complementary and Integrative Health (NCCIH).
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 51 participants
- Enrollment target
Study Summary
RATIONALE: Drugs used in chemotherapy, such as gemcitabine, use different ways to stop tumor cells from dividing so they stop growing or die. Mistletoe may slow the growth of tumor cells and may be an effective treatment for solid tumors. PURPOSE: Phase I trial to study the effectiveness of combining gemcitabine with mistletoe in treating patients who have advanced solid tumors.
Interventions
- DRUG gemcitabine hydrochloride
- DIETARY_SUPPLEMENT mistletoe extract
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 51 participants |
| Start Date | 2002-07 |
| Est. Completion | 2011-08 |
| Phase | Phase 1 |
Why NCT00049608 stopped before completion
NCT00049608 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 51 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (15% lower).
The record links to 0 conditions, and to 2 interventions - of which gemcitabine hydrochloride is the first listed.
NCT00049608 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00049608 about?
NCT00049608 is a clinical study titled "Gemcitabine Combined With Mistletoe in Treating Patients With Advanced Solid Tumors". RATIONALE: Drugs used in chemotherapy, such as gemcitabine, use different ways to stop tumor cells from dividing so they stop growing or die. Mistletoe may slow the growth of tumor cells and may be an effective treatment for solid tumors. PURPOSE: Phase I trial to study the effectiveness of combini...
What is the current status of trial NCT00049608?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 51 participants. The study started on 2002-07. Estimated completion is 2011-08.
What interventions are being tested in trial NCT00049608?
The interventions under investigation include: gemcitabine hydrochloride (DRUG), mistletoe extract (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT00049608?
This trial is sponsored by National Center for Complementary and Integrative Health (NCCIH), which has 203 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00049608's enrollment target sits among peer trials
51 969th of 2000 higher than 1,028 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02701153 · 51 participants · NA
Phase II Study of 5-Day Hypofractionated Preoperative Radiation Therapy for Soft Tissue Sarcomas: Expansion Cohort
- NCT03663790 · 51 participants · NA
Effects of Gait Retraining on Lower Extremity Biomechanics
- NCT03874052 · 51 participants · Phase 1
Ruxolitinib in Combination With Venetoclax With and Without Azacitidine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
- NCT04704661 · 51 participants · Phase 1
Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia